Algiax Pharmaceuticals appoints Prof. Claudia Sommer and Dr. Klaus-Dieter Langner to join its Scientific Advisory Board

DÜSSELDORF, Germany–(BUSINESS WIRE)–<a href="https://twitter.com/hashtag/koopmans?src=hash" target="_blank">#koopmans</a>–Algiax Pharmaceuticals, a clinical-stage biotechnology company focused on development of GABAA receptor modulators for neuropathic pain and other indications with unmet medical need, announced the appointment of Prof. Dr. med. Claudia Sommer and Dr. Klaus-Dieter Langner as members of Algiax´scientific advisory board. Claudia Sommer is a Professor of Neurology at the University of Würzburg, Germany, with a focus on peripheral neurology and pain. She has writ http://www.businesswire.com/news/home/20190718005043/en/Algiax-Pharmaceuticals-appoints-Prof.-Claudia-Sommer-Dr./?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==